Publicación: Experiencia con 12 ciclos de quimioembolizacion arterial en pacientes con hepatocarcinoma o metástasis ahigado con primario controlado Bucaramanga Colombia
| dc.contributor.advisor | Insuasty Enriquez, Jesus Solier | |
| dc.contributor.author | Bracho Churio, Madeleine Lucia | |
| dc.date.accessioned | 2024-03-03T17:05:46Z | |
| dc.date.available | 2008 | |
| dc.date.available | 2024-03-03T17:05:46Z | |
| dc.date.created | 2008 | |
| dc.date.issued | 2008 | |
| dc.description.abstract | Describir la respuesta al tratamiento con Quimioembolizacion Intraarterial Hepática Supraselectiva (QEIAHS) del hepatocarcinoma u otras neoplasias metastasicas al hígado con primario controlado. Estudio descriptivo: serie de casos. Se revisaron las historias clínicas de pacientes sometidos a QEIAHS, tratados en la Unidad de Oncología del Hospital Universitario de Santander a partir de marzo de 2000. RESULTADOS: Se realizaron 12 procedimientos de QEIAHS en 6 pacientes con excelente reserva hepática. Edades por encima de la quinta década. Diagnósticos histopatologicos: 2 pacientes con hepatocarcinoma, una con tumor carcinoide metastásico a hígado, dos con colangiocarcinoma confinado al hígado y uno con adenocarcinoma de sigmoides metastásico al hígado. Tamaños tumorales predominantes entre 5 y 12 cm. Síntoma predominante: dolor abdominal grado 2. ChildPugh A, Okuda I. Estados funcionales mejores o iguales a 1 Respuesta evaluada cuatro semanas después de la aplicación de cada ciclo de QEIAHS. A los pacientes 1 y 2 se les realizaron 3 ciclos, al paciente 3, 4 ciclos y a los pacientes 4 y 6, un solo ciclo. A la paciente 5 no se le realizo el procedimiento por la presencia de arterioesclerosis. Mejores respuestas paliativas alcanzadas: 50- 93%. El paciente 4, presento progresión. Los eventos adversos fueron mínimos, transitorios y de fácil manejo, sin efectos hematológicos. Solo tuvimos un síndrome postquimioembolizacion en la paciente 1, que respondió al manejo. Tiempo de seguimiento promedio: 11,2 meses. Mediana de sobrevida: 16 meses. Sobrevida total: 27%. Los estados funcionales se mantuvieron entre grado 0 y 1 durante el periodo de sobrevida, permaneciendo generalmente asintomáticos. CONCLUSIONES: Surge la QEIAHS, como alternativa terapéutica paliativa para el tratamiento de pacientes con estos diagnósticos, con efectos colaterales mínimos, buenas respuestas de paliación, manteniendo excelente estado funcional. Es aplicable en sitios que cuenten con Unidades de Oncología y hemodinamia y facilitado por el Plan Obligatorio de Salud. | |
| dc.description.abstractenglish | To describe the response to the treatment with Superselective Hepatic Intraarterial Chemoembolization (SHIACE) of hepatocarcinoma, or other metastatic neoplasias of theliver with controlled trial. Descriptive study: series of cases. Clinical histories, which were reviewed,included consecutive patients undergoing SHIACE with an established diagnosis of primary hepatictumors or patients with liver metastasis with controlled primary. All patients were treated in theDepartment of Oncology at the University Hospital of Santander since March, 2000. RESULTS: 6 patients with an excellent hepatic reserve underwent 12 procedures of SHIACE. Theiraverage age was over fifty. The histopatologic diagnosis corresponded to two patients withhepatocellular carcinoma, one patient with metastatic carcinoid tumor to the liver, two patients witha diagnosis of cholangiocarcinoma confined to the liver, and one patient with a diagnosis ofmetastatic sigmoids adenocarcinoma of the liver. The basal predominant tumors were between 5and 12 cm. The predominant symptom was the second-degree abdominal pain. The states of ChildPugh and Okuda, were A and | respectively. Also, all the functional states at the beginning werebetter or equal to 1 The results were evaluated four weeks after the application of each course of SHIACE. Threecourses were applied for patients 1 and 2, four courses for patient 3, and a single course forpatients 4 and 6. Patient 5 did not undergo the procedure because of the presence ofarteriosclerosis. The best-reached palliative answers were between 50 and 93%. Patient 4displayed progression. The side effects were minimum, transitory and medically easy to handle.The absence of hematologic effects stood out. There was only one case of PostChemoembolization Syndrome found in patient 1, who responded to the restored handling. Theaverage time for monitoring was 11.2 months. Median survival: 16 months. Survival rate: 27%. Thefunctional states stayed between 0 degree and 1 degree during the survival period, remaininggenerally asymptomatic. CONCLUSIONS: The SHIACE, through a selective transitory femoral percutaneous catheterizationof the main artery by angiography of the celiac trunk, has been revealed to be a therapeuticalternative. It is a palliative for the treatment of patients with hepatic primary tumors and/ormetastatic tumors confined to the liver, with minimum side effects and good responses, maintainingan excellent functional state. The SHIACE is an applicable procedure in the majority of the places inColombia with departments of Oncology and Hemodinamia. Simultaneously, this procedure isfacilitated by the Obligatory Plan of Health of Colombia, which contemplates the use of differentdrugs and the accomplishment of a peripheral arterial-graph. These are the necessary conditions toexecute this procedure. | |
| dc.description.degreelevel | Especialización | |
| dc.description.degreename | Especialista en Medicina Interna | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.instname | Universidad Industrial de Santander | |
| dc.identifier.reponame | Universidad Industrial de Santander | |
| dc.identifier.repourl | https://noesis.uis.edu.co | |
| dc.identifier.uri | https://noesis.uis.edu.co/handle/20.500.14071/21303 | |
| dc.language.iso | spa | |
| dc.publisher | Universidad Industrial de Santander | |
| dc.publisher.faculty | Facultad de Salud | |
| dc.publisher.program | Especialización en Medicina Interna | |
| dc.publisher.school | Escuela de Medicina | |
| dc.rights | http://creativecommons.org/licenses/by/4.0/ | |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) | |
| dc.rights.license | Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0 | |
| dc.subject | Quimioembolizacion arterial | |
| dc.subject.keyword | Arterial Chemoembolization | |
| dc.title | Experiencia con 12 ciclos de quimioembolizacion arterial en pacientes con hepatocarcinoma o metástasis ahigado con primario controlado Bucaramanga Colombia | |
| dc.title.english | A 12 course experience of arterial chemoembolization in patients with hepatocellular carcinoma or liver metastasis with controlled trial bucaramanga œ colombia. | |
| dc.type.coar | http://purl.org/coar/version/c_b1a7d7d4d402bcce | |
| dc.type.hasversion | http://purl.org/coar/resource_type/c_7a1f | |
| dc.type.local | Tesis/Trabajo de grado - Monografía - Pregrado | |
| dspace.entity.type | Publication |